"According to Globe Newswire, the global therapeutic peptide drug market was worth $25.35 billion in 2018, which is expected to reach $50.6 billion by 2026, at a compound annual growth rate of 9.0%. Peptide drugs will be used as targeted drugs for the treatment of cancer, metabolic disorders, and cardiovascular diseases [4]. Biotech companies represented by Oncopeptides, Angiochem, PeptiDream. Mainline Bioscience and Theratechnologies have achieved significant technological breakthroughs after years of dedicated research, coupled with capital driving and accelerated audit speed. As a result, more and more PDC drugs with different indications exist in the clinical I/II phase, especially, those antitumor PDC drugs will open up the CDMO market at a rapid pace.
Drug Name Company Therapeutic Area Highest Clinical Phase
Melflufen Oncopeptides Cancer Phase 3
ANG1005 Angiochem Cancer Phase 3
MLB1707 Mainline Bioscience Cancer Phase 2
BT1718 Bicycle Therapeutics Cancer Phase 1
TH1902 Theratechnologies Cancer Pre-Clinical
TH1904 Theratechnologies Cancer Pre-Clinical"